Cytokine storm and translating IL-6 biology into effective treatments for CoVID-19
作者机构:Department of Geriatric MedicineThe First Affiliated Hospital of USTCDivision of Life Sciences and MedicineUniversity of Science and Technology of ChinaHefei 230001China Respiratory and Critical Care MedicineThe First Afiliated Hospital of USTCDivision of Life Sciences and MedicineUniversity of Science and Technology of ChinaHefei 230001China Institute of Immunology and the CAS Key Laboratory of Innate Immunity and Chronic DiseaseSchool of Life Science and Medical CenterUniversity of Science and Technology of ChinaHefei 230001China Hefei National Laboratory for Physical Sciences at MicroscaleUniversity of Science and Technology of ChinaHefei 230001China
出 版 物:《Frontiers of Medicine》 (医学前沿(英文版))
年 卷 期:2023年第17卷第6期
页 面:1080-1095页
核心收录:
学科分类:1002[医学-临床医学] 100201[医学-内科学(含:心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题:SARS-CoV-2 COVID-19 cytokine storm interleukin-6 tocilizumab
摘 要:As of May 3,2023,the Coronavirus disease 2019(COVID-19)pandemic has resulted in more than 760 million confirmed cases and over 6.9 million *** patients have developed pneumonia,which can deteriorate into acute respiratory distress *** primary etiology may be attributed to cytokine storm,which is triggered by the excessive release of proinflammatory cytokines and subsequently leads to immune *** that high levels of interleukin-6(IL-6)have been detected in several highly pathogenic coronavirus-infected diseases,such as severe acute respiratory syndrome in 2002,the Middle East respiratory syndrome in 2012,and COVID-19,the IL-6 pathway has emerged as a key in the pathogenesis of this hyperinflammatory ***,we review the history of cytokine storm and the process of targeting IL-6 signaling to elucidate the pivotal role played by tocilizumab in combating COVID-19.